We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CTI Appeals FDA’s Rejection of Pixantrone for Lymphoma
CTI Appeals FDA’s Rejection of Pixantrone for Lymphoma
September 17, 2010
Cell Therapeutics (CTI) believes the FDA erred in denying its NDA for pixantrone to treat patients with relapsed or refractory, aggressive non-Hodgkin’s lymphoma (NHL), saying its single clinical trial of the drug met all primary and secondary endpoints in the patient population.